“Internationally, the stapler is now in broad launch across Europe and Korea with positive early adoption and we expect availability to extend to Japan in Q3.”

In context

“t positive reimbursement decisions by the Japanese Ministry of Health Labor and Welfare. While da Vinci adoption for benign procedures in OUS markets remains at an early stage, we estimate it represents just over 25% of our international business and volume growth in this category accelerated to 37% in Q2. This will remain an ongoing area of focus. SP procedures grew 61% in the quarter powered by strength in the US and Korea, and encouraging early stage momentum in Europe, Japan and Taiwan. In the United States, SP average system utilization accelerated from Q1 expanding 25% compared with the second quarter of last year, Our SP stapler launch continued to progress well in the US, where it is in broad release, it was used in nearly 60% of eligible cases up from just under 40% last quarter. Internationally, the stapler is now in broad launch across Europe and Korea with positive early adoption and we expect availability to extend to Japan in Q3. Total I and A revenue in quarter 2 grew 18% to $1.73 billion da Vinci I&A revenue per procedure increased approximately $1.83 thousand compared to $1.8 thousand last year driven by a higher mix of SP and da Vinci 5 procedures offset by customer ordering patterns higher cholecystectomy procedures, and lower bariatric procedures. The decline in revenue per procedure from last quarter can largely be attributed to customer ordering patterns which were elevated in Q1 especially in OUS markets. Beginning in the first half of 27, we plan to introduce an updated subset of ENDORIST instruments for use with our fourth and fifth generation da Vinci platforms that feature increased useful lives and lower customer cost per use. The lower cost for customers is targeted towards high volume benign proced”